Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies. IBM is a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.
Location: United States
Employees: 11-50
Total raised: $397M
Founded date: 2015
Investors 6
| Date | Name | Website |
| - | ShangPharm... | spiivc.com |
| - | Myeloma In... | myelomainv... |
| - | RA Capital... | racap.com |
| 28.05.2024 | Bain Capit... | baincapita... |
| 25.08.2023 | New Leaf V... | nlvpartner... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 18.08.2026 | Series D | $66M | New Enterp... |
| 19.02.2025 | Series C | $200M | - |
| 18.08.2023 | Series B | $155M | - |
| 07.01.2021 | Series A | $42M | - |
Mentions in press and media 14
| Date | Title | Description |
| 18.08.2026 | Venture Capital & Startup Funding Roundup, August 18, 2026: Andreessen Horowitz, Jane Street, Kleiner Perkins, Sequoia, Tiger Global & More | Artificial intelligence has dominated the news for months. But today’s venture capital is moving deeper into the technology stack. Rather than chasing another wave of generic AI software, investors are backing the infrastructure, energy eff... |
| 18.08.2026 | Abcuro Raises $66M in Series D Funding | Abcuro, a Newton, MA-based clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, raised $66M in Series D funding. The round was led by New Leaf Ve... |
| 18.08.2026 | Grounded Raises $5M in Seed Funding | Grounded, a Detroit, MI-based advanced manufacturing and mobility company known for its modular electric vehicles, raised $5M in Seed funding. Backers were not disclosed. The company intends to use the funds to stand up its new box platform... |
| 19.02.2025 | Abcuro: $200 Million (Series C) Raised For Advancing Medicine In Development For Inclusion Body Myositis | Abcuro – a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells – announced the closing of a $200 million Series C financing led by New... |
| 13.02.2025 | Abcuro Raises $200M in Series C Financing | Abcuro, a Newton, MA-based clinical-stage biotechnology company, raised $200M in Series C funding. The round was led by New Enterprise Associates (NEA) joined by Foresite Capital with participation from existing investors including RA Capit... |
| 12.02.2025 | Sanofi-backed Abcuro raises $200M series C to fund pivotal trial of KLRG1 antibody | Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle disease trial ahead of a planned push to regulators. Abcuro is targeting KLRG1 to drive the depletion of cytotoxic T... |
| 29.09.2023 | Eurofarma anuncia un fondo de 100M$ para invertir en startups biotechs | Eurofarma, compañía farmacéutica brasileña con presencia en América Latina y EE. UU., ha anunciado el lanzamiento de un fondo corporativo de 100 millones de dólares para invertir en startups del ámbito biotecnológico, que tengan proyectos e... |
| 18.08.2023 | Abcuro Raises $155M in Series B Financing | Abcuro, a Newton, MA-based clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer, raised $155M in Series B funding. The round was co-led by Redmile Group and Bain Capital Life Sciences... |
| 17.08.2023 | Sanofi-backed Abcuro loads up with $155M series B to push KLRG1 antibody through clinic | Abcuro will draw on an oversubscribed series B round to continue the journey of its anti-KLRG1 candidate through clinical trials for a muscle disease and cancers. The latest round of $155 million follows a $42 million series A co-led by San... |
| 07.10.2022 | Sanofi's BD chief heads to Owkin as CBO; Roche relies on its bench for Thomas Schinecker’s diagnostics replacement | Alban de La Sablière Up until recently, Alban de La Sablière was Sanofi’s chief dealmaker, reporting directly to CEO Paul Hudson without officially being a C-suite executive. That’s now changed with de La Sablière’s newe... |
Show more